Astellas Pharma Inc. (4503)

2,016.0 -34.0 (-1.66%)
Close JPY Disclaimer

Astellas Pharma Inc. Company Profile

Industry
Pharmaceuticals
Sector
Healthcare
Employees
15455
Equity Type
ORD
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Contact Information
Address
Tokyo,103-8411 Japan
Phone
81 3 3244 3000
Fax
-
Top Executives
Name
Age
Since
Title
Kenji Yasukawa 62 2017 President, CEO & Chairman of the Board
Toru Yoshimitsu 0 2020 Director
Naoki Okamura 0 2016 Executive VP, Chief Strategy Officer & Representative Director
Mamoru Sekiyama 0 2017 Independent Outside Director
Hiroshi Kawabe 0 2019 Independent Outside Director
Raita Takahashi 60 2020 Independent Outside Director
Eriko Sakurai 62 2022 Independent Outside Director
Haruko Shibumura 58 2019 Independent Outside Director
Mika Nakayama 0 2022 Independent Outside Director
Takashi Tanaka 65 2021 Independent Outside Director
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles